Carcinogenesis, Teratogenesis & Mutagenesis ›› 2024, Vol. 36 ›› Issue (3): 208-218.doi: 10.3969/j.issn.1004-616x.2024.03.007

Previous Articles     Next Articles

Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms

SONG Zhenming1,2, YU Yunliang2, YANG Jinmei2, LIU Kun2, GAI Chanchan2, MA Chunyu1   

  1. 1. School of Basic Medical Sciences of Jinzhou Medical University, Jinzhou 121001, Liaoning;
    2. Department of Medical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, Shandong, China
  • Received:2023-03-04 Revised:2023-09-26 Online:2024-05-30 Published:2024-06-05

Abstract: OBJECTIVE:To investigate correlations between purinergic receptor X1 (P2RX1) and different clinical pathological factors and tumor infiltration parameters in patients with ovarian serous carcinoma (OV),and to provide new clues for OV immunotherapy. METHODS:Serum samples and tissues were collected from OV patients. Healthy adults and non-cancer patients were used as controls. Immunohistochemistry (IHC),reverse transcriptation fluorescence quantitative PCR (RT-qPCR),enzyme-linked immunosorbent assay (ELISA) and bioinformatics methods were used to determine expression patterns of P2RX1 in samples from patients. The TCGA database was used to analyze correlations between expression levels of P2RX1 and different clinicopathological indicators in the patients;to screen differential gene expressions,to identify signaling pathways and biological functions of P2RX1;and to analyze correlations between P2RX1 and immune cell infiltration abundance and tumor immunity. RESULTS:The IHC results show that P2RX1 was mainly expressed in normal ovarian epithelium;the RT-qPCR results show that expression of P2RX1 mRNA was lower in OV than in non-cancer tissues (P<0.05);the ELISA results show that the expression of P2RX1 protein in the serum of the patients was lower than that of normal healthy adults (P<0.05). Results from analysis of the TCGA database show that patients with higher expression of P2RX1 had longer survival rates and better prognosis (P<0.05) than those with lower expressions. P2RX1 was associated with tumor purity and age of the patients (P<0.05). Results from the enrichment analysis show that the differentially expressed genes of P2RX1 were mainly enriched in biological processes such as immune cell differentiation and development. P2RX1 was found to be associated with multiple immune checkpoints in OV,such as TGFB1,SLAMF7,and CD27. P2RX1 was significantly and positively correlated with B cell marker genes such as CD79A,CD79B,and CD19 in OV (r>0.4,P<0.05). CONCLUSION:Low expression of P2RX1 in OV was associated with poor prognosis in patients. P2RX1 might be involved in processes such as immune cell infiltration and differentiation in the microenvironment of OV patients.

Key words: purinergic receptor X1, ovarian serous carcinoma, prognosis, immunotherapy

CLC Number: